Nortriptyline

The selected labels indicate relief of depressive symptoms; they note stronger response in endogenous depressive states. Nortriptyline is not approved for pediatric use or bipolar depression. Screen for bipolar illness before antidepressant treatment. No off-label pain, migraine or smoking-cessation regimen is asserted here.

Usual adult label dose is 25 mg three or four times daily; the total daily dose may alternatively be taken once daily. Begin below the usual regimen when appropriate and increase gradually according to benefit and intolerance. Doses above 150 mg/day are not recommended. Above 100 mg/day, measure nortriptyline plasma concentration and maintain the label range of 50–150 ng/mL.

The label lists 30–50 mg/day in divided doses or once daily for elderly and adolescent patients, while explicitly stating pediatric use is unapproved and not established. This historical adolescent dosing text is not evidence of pediatric approval. Older adults should receive the smallest effective dose. Oral solution is 10 mg/5 mL; measure a prescribed volume with a calibrated device. The selected solution contains 4% alcohol.

Allow at least 14 days after stopping a psychiatric MAOI before starting nortriptyline, and at least 14 days after stopping nortriptyline before starting that MAOI. Do not initiate nortriptyline during linezolid or IV methylene blue treatment. If urgent use of either is unavoidable after alternatives are assessed, the label requires promptly stopping nortriptyline, monitoring for serotonin syndrome for two weeks or until 24 hours after the last MAOI dose, whichever comes first, and waiting 24 hours after that dose before resumption. This is a supervised exception, not a routine overlap.

After remission, continued maintenance at the lowest effective dose may be needed. Reduce dose for minor intolerance; promptly reassess serious adverse effects or allergy. Abrupt cessation after prolonged use can cause nausea, headache and malaise; plan discontinuation with the prescriber. The selected labels supply no universal taper schedule.

Contraindicated during acute recovery after myocardial infarction and with psychiatric MAOIs, including the bidirectional 14-day washouts. Starting during linezolid or IV methylene blue is contraindicated. The hypersensitivity subsection warns of potential cross-sensitivity with other tricyclic/dibenzazepine drugs; review prior allergic reactions and avoid implicated products. Brugada risk is a generally-avoid warning rather than a separately listed formal contraindication.

Both selected oral labels carry the antidepressant suicidality boxed warning: short-term studies found increased suicidal thinking/behavior in children, adolescents and young adults. This warning requires balancing clinical need and close observation; it does not establish pediatric approval. Depression itself also carries suicide risk, and every age requires appropriate monitoring.

Anticholinergic effects include dry mouth, constipation, blurred vision and urinary retention; drowsiness, dizziness, sweating and weight changes may occur. Serious reported or class-listed reactions include arrhythmias, heart block, seizures, mania/confusion, blood dyscrasias, liver injury, SIADH and severe allergy. Label lists include some class events not specifically observed with nortriptyline and do not provide a reliable incidence for each. Overdose may rapidly cause dysrhythmia, hypotension, seizures or coma and death: obtain emergency help and poison-center guidance immediately; do not induce vomiting.

Review every prescription, nonprescription drug and supplement. Exposure-based dose changes and drug-level monitoring are clinician decisions.

Safety during pregnancy and lactation has not been established in the selected labels; weigh maternal benefit against potential fetal or infant hazards. Animal studies were inconclusive. Make pregnancy and breastfeeding decisions with the treating team rather than asserting safety from absent data.

Safety and effectiveness in pediatric patients are unestablished. Older patients may develop confusion, blood-pressure changes, arrhythmias or higher active-metabolite concentrations; monitor cardiovascular function and use the lowest effective total dose. Rare geriatric cholestatic liver injury, including fatal reports, is described.

The selected labels do not establish a numerical renal or hepatic dose-adjustment regimen. Individualize dose using tolerability, clinical response and concentration monitoring when indicated. CYP2D6 inhibition or reduced metabolism can substantially increase exposure; suspected liver injury requires prompt assessment. Do not turn these observations into an unsupported organ-dose algorithm.

The labels describe the precise mood-elevating mechanism as unknown and catecholamine transport, release and storage effects as implicated. Nortriptyline is not an MAO inhibitor. Anticholinergic and cardiovascular actions account for clinically important tolerability limitations.

CYP2D6 poor metabolism or inhibition can increase TCA exposure. Older adults may have higher concentrations of 10-hydroxynortriptyline. The selected clinical-pharmacology sections do not provide a complete quantitative absorption, half-life or renal-clearance profile; none is invented here. Therapeutic concentrations do not replace ECG and clinical assessment in overdose.

Assess depression response, suicidal thinking, activation/mania, blood pressure and pulse, anticholinergic burden and falls. Monitor cardiovascular function particularly with cardiac disease or older age. Measure plasma levels above 100 mg/day and when CYP2D6 interactions warrant. Serious toxicity or suspected overdose needs urgent ECG/cardiac monitoring, not reassurance from a drug level.

Read the Medication Guide; report worsening mood, agitation, suicidal thoughts or unusual behavior promptly. Seek urgent care for collapse, seizure, severe palpitations, fever with rigidity/confusion, or acute painful visual changes. Avoid hazardous activities until effects are known, discuss alcohol avoidance, store securely and use the smallest clinically appropriate quantity to reduce overdose risk. Do not stop or change dose independently.

Sun/Taro 25 mg capsule: opaque ivory cap and body, marked TARO and NTP25; selected bottle of 30 NDC 51672-4002-6. This is an identification example, not a guarantee of stock or a substitute for package verification.

Selected capsules contain 10, 25, 50 or 75 mg equivalent base. PAI oral solution contains 10 mg/5 mL and 4% alcohol; selected 473 mL bottle NDC 0121-0678-16. Confirm concentration and ingredients on the actual package before converting a prescribed milligram dose to volume.

Selected capsules and solution: store at 20–25°C. Capsules require a tight container with child-resistant closure; solution requires a tight, light-resistant container. Keep securely away from children and protect against accidental or intentional overdose.